Evaluation of Dalbavancin in Vancomycin Allergic Patients: A Case Series



      There is a paucity of data regarding dalbavancin use in patients with a vancomycin allergy because of potential cross-reactivity between the 2 glycopeptide antibiotics.


      A retrospective medical record review was performed between February 2016 and February 2021 in patients with a listed vancomycin allergy who received dalbavancin as an outpatient infusion and had a listed vancomycin allergy in the electronic health record.


      There were 559 unique patients during the study period who received dalbavancin as an outpatient infusion, 10 of whom had a documented vancomycin allergy in the electronic health record. Four of the 10 patients had a history of a type I IgE-mediated reaction to vancomycin, 1 patient reported delayed rash, 2 patients reported a vancomycin infusion reaction, 2 patients reported acute kidney injury, and 1 patient reported intolerance with general malaise. All 10 patients received at least 1 dose of dalbavancin with no reported adverse events.


      This case series displays that all patients who received dalbavancin tolerated the infusion well with no adverse events reported. Dalbavancin may be a viable option for patients with a listed vancomycin allergy.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. Dalvance (dalbavancin) [prescribing information].
        Allergan USA, Inc., Madison, NJ2021 (Accessed 22 Apr 2022)
        • Gatti M
        • Andreoni M
        • Pea F
        • Viale P.
        Real-World Use of Dalbavancin in the Era of Empowerment of Outpatient Antimicrobial Treatment: A Careful Appraisal Beyond Approved Indications Focusing on Unmet Clinical Needs.
        Drug Des Devel Ther. 2021; 15: 3349-3378
        • Bambeke FV.
        Glycopeptides in clinical development: pharmacological profile and clinical perspectives.
        Curr Opin Pharmacol. 2004; 4: 471-478
        • Ishizuka KT
        • Tran TK
        • Ayars AG
        • Chau AS
        • Chan JD.
        Graded dalbavancin challenge in a patient with severe vancomycin hypersensitivity reaction.
        Clin Infect Dis. 2020; 70: 1230-1232
        • Nakkam N
        • Gibson A
        • Mouhtouris E
        • et al.
        Cross-reactivity between vancomycin, teicoplanin, and telavancin in patients with HLA-A∗32:01-positive vancomycin-induced DRESS sharing an HLA class II haplotype.
        J Allergy Clin Immunol. 2021; 147: 403-405
        • Rybak MJ
        • Le J
        • Lodise TP
        • et al.
        Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists.
        Clin Infect Dis. 2020; 71: 1361-1364
        • Bland CM
        • Crosby CM
        • Orvin DL
        • Smith SE
        • Jones BM.
        Transitioning from guideline approval to practical implementation of AUC-based monitoring of vancomycin.
        Am J Health Syst Pharm. 2021; 78: 1270-1272
      2. Orbactiv (oritavancin) [prescribing information].
        Melinta Therapeutics, Inc., 2019 (Accessed April 22, 2022)
        • Dunne MW
        • Puttagunta S
        • Giordano P
        • Krievins D
        • Zelasky M
        • Baldassarre J.
        A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection.
        Clin Infect Dis. 2016; 62: 545-551
        • Nakkam N
        • Gibson A
        • Mouhtouris E
        • Kovinse K
        • et al.
        Cross-reactivity between vancomycin, teicoplanin and telavancin in HLA-A*32:01 positive vancomycin DRESS patients sharing an HLA-Class II haplotype.
        J Allergy Clin Immunol. 2021; 147: 403-405
        • Solensky R
        • Khan DA
        • Bernstein IL
        • et al.
        Drug allergy: an updated practice parameter.
        Ann Allergy Asthma Immunol. 2010; 105: 259-273
        • Jones BM
        • Hersey R
        • Taylor C
        • Bland CM.
        Evaluation of dalbavancin on length of stay in acute bacterial skin and structure infections.
        J Am Coll Clin Pharm. 2019; 2: 477-481
        • Pizzuti AG
        • Murray EY
        • Wagner JL
        • Gaul GA
        • Bland CM
        • Jones BM.
        Financial analysis of dalbavancin for acute bacterial skin and skin structure infections for self-pay patients.
        Infect Dis Ther. 2020; 9: 1043-1053
        • Antosz K
        • Al-Hasan MN
        • Lu ZK
        • et al.
        Clinical utility and cost effectiveness of long-acting lipoglycopeptides used in deep-seated infections among patients with social and economic barriers to care.
        Pharmacy. 2021; 10: 1